Insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Alector, Inc. (ALEC) since 2019 are shown in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Alector, Inc.. Table 2 shows the detailed insider transactions. This company's CIK number is 1653087.
Total stock buying since 2019: $16,144,600.
Total stock sales since 2019: $179,123,828.
Total stock option exercises since 2019: $11,137,003.
| Insider Buying | Insider Sales | Option Exercises | ||||
|---|---|---|---|---|---|---|
| Year | Shares | Value | Shares | Value | Shares | Value |
| 2025 | 0 | $0 | 308,217 | $552,515 | 0 | $0 |
| 2024 | 0 | $0 | 320,027 | $1,396,162 | 0 | $0 |
| 2023 | 0 | $0 | 1,110,407 | $6,692,135 | 0 | $0 |
| 2022 | 0 | $0 | 2,609 | $24,687 | 0 | $0 |
| 2021 | 0 | $0 | 1,719,215 | $44,005,185 | 801,959 | $10,279,812 |
| 2020 | 20,000 | $500,000 | 3,410,778 | $85,396,956 | 82,921 | $688,558 |
| 2019 | 823,400 | $15,644,600 | 2,212,466 | $41,056,188 | 20,666 | $168,633 |
| Trading Period | Insider Buying | Insider Sales | Option Exercises | |||
|---|---|---|---|---|---|---|
| year-month | Shares | Value | Shares | Value | Shares | Value |
| 2025-09 | 0 | $0 | 96,952 | $242,088 | 0 | $0 |
| 2025-08 | 0 | $0 | 14,000 | $32,998 | 0 | $0 |
| 2025-06 | 0 | $0 | 93,465 | $125,156 | 0 | $0 |
| 2025-03 | 0 | $0 | 103,800 | $152,273 | 0 | $0 |
| 2024-12 | 0 | $0 | 110,053 | $277,221 | 0 | $0 |
| 2024-09 | 0 | $0 | 56,200 | $274,392 | 0 | $0 |
| 2024-08 | 0 | $0 | 59,750 | $306,866 | 0 | $0 |
| 2024-06 | 0 | $0 | 53,301 | $255,789 | 0 | $0 |
| 2024-03 | 0 | $0 | 40,723 | $281,894 | 0 | $0 |
| 2023-12 | 0 | $0 | 45,959 | $255,530 | 0 | $0 |
| 2023-09 | 0 | $0 | 1,015,746 | $6,081,789 | 0 | $0 |
| 2023-06 | 0 | $0 | 13,014 | $89,847 | 0 | $0 |
| 2023-03 | 0 | $0 | 35,688 | $264,969 | 0 | $0 |
| 2022-12 | 0 | $0 | 2,145 | $18,678 | 0 | $0 |
| 2022-06 | 0 | $0 | 177 | $1,541 | 0 | $0 |
| 2022-03 | 0 | $0 | 287 | $4,468 | 0 | $0 |
| 2021-12 | 0 | $0 | 300,250 | $6,705,747 | 300,000 | $4,906,875 |
| 2021-11 | 0 | $0 | 510,000 | $12,750,000 | 0 | $0 |
| 2021-09 | 0 | $0 | 309,625 | $8,047,068 | 2,000 | $36,200 |
| 2021-08 | 0 | $0 | 79,210 | $2,204,392 | 79,210 | $841,676 |
| 2021-07 | 0 | $0 | 300,630 | $10,036,873 | 201,249 | $2,470,525 |
| 2021-05 | 0 | $0 | 19,175 | $347,460 | 19,175 | $175,451 |
| 2021-04 | 0 | $0 | 22,300 | $435,117 | 22,300 | $263,519 |
| 2021-03 | 0 | $0 | 62,975 | $1,349,940 | 62,975 | $532,859 |
| Trade Date | Insider Name | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2025-09-02 | Berkley Neil Lindsay (Principal Financial Officer) | Sale | 15,842 | 2.50 | 39,557 |
| 2025-09-02 | Wong-sarad Grace (Principal Accounting Officer) | Sale | 5,910 | 2.50 | 14,757 |
| 2025-09-02 | Kenkare-mitra Sara (President and Head of R&D) | Sale | 23,638 | 2.50 | 59,024 |
| 2025-09-02 | Rosenthal Arnon (Chief Executive Officer) | Sale | 51,562 | 2.50 | 128,750 |
| 2025-08-26 | Hammond Paula | Sale | 14,000 | 2.36 | 32,998 |
| 2025-06-20 | Yaffe Kristine | Sale | 1,000 | 1.44 | 1,440 |
| 2025-06-02 | Kenkare-mitra Sara (President and Head of R&D) | Sale | 23,890 | 1.34 | 31,964 |
| 2025-06-02 | Rosenthal Arnon (Chief Executive Officer) | Sale | 52,087 | 1.34 | 69,692 |
| 2025-06-02 | Grasso Marc (Chief Financial Officer) | Sale | 16,488 | 1.34 | 22,060 |
| 2025-03-03 | Kenkare-mitra Sara (President and Head of R&D) | Sale | 29,073 | 1.47 | 42,650 |
| 2025-03-03 | Romano Gary (Chief Medical Officer) | Sale | 16,306 | 1.47 | 23,920 |
| 2025-03-03 | Rosenthal Arnon (Chief Executive Officer) | Sale | 40,330 | 1.47 | 59,164 |
| 2025-03-03 | Grasso Marc (Chief Financial Officer) | Sale | 18,091 | 1.47 | 26,539 |
| 2024-12-02 | Kenkare-mitra Sara (President and Head of R&D) | Sale | 26,500 | 2.52 | 66,753 |
| 2024-12-02 | Romano Gary (Chief Medical Officer) | Sale | 14,892 | 2.52 | 37,512 |
| 2024-12-02 | Rosenthal Arnon (Chief Executive Officer) | Sale | 52,172 | 2.52 | 131,421 |
| 2024-12-02 | Grasso Marc (Chief Financial Officer) | Sale | 16,489 | 2.52 | 41,535 |
| 2024-09-03 | Kenkare-mitra Sara (President and Head of R&D) | Sale | 13,926 | 4.88 | 67,986 |
| 2024-09-03 | Romano Gary (Chief Medical Officer) | Sale | 8,478 | 4.88 | 41,389 |
| 2024-09-03 | Rosenthal Arnon (Chief Executive Officer) | Sale | 26,499 | 4.88 | 129,394 |
| 2024-09-03 | Grasso Marc (Chief Financial Officer) | Sale | 7,297 | 4.88 | 35,623 |
| 2024-08-22 | Scheller Richard H | Sale | 44,250 | 5.16 | 228,374 |
| 2024-08-12 | Hammond Paula | Sale | 10,500 | 5.07 | 53,182 |
| 2024-08-12 | Yaffe Kristine | Sale | 5,000 | 5.06 | 25,310 |
| 2024-06-03 | Kenkare-mitra Sara (President and Head of R&D) | Sale | 13,206 | 4.80 | 63,375 |
| 2024-06-03 | Romano Gary (Chief Medical Officer) | Sale | 8,040 | 4.80 | 38,583 |
| 2024-06-03 | Rosenthal Arnon (Chief Executive Officer) | Sale | 25,135 | 4.80 | 120,622 |
| 2024-06-03 | Grasso Marc (Chief Financial Officer) | Sale | 6,920 | 4.80 | 33,209 |
| 2024-03-04 | Kenkare-mitra Sara (President and Head of R&D) | Sale | 10,169 | 6.92 | 70,389 |
| 2024-03-04 | Romano Gary (Chief Medical Officer) | Sale | 6,001 | 6.92 | 41,556 |
| 2024-03-04 | Rosenthal Arnon (Chief Executive Officer) | Sale | 18,837 | 6.92 | 130,389 |
| 2024-03-04 | Grasso Marc (Chief Financial Officer) | Sale | 5,716 | 6.92 | 39,560 |
| 2023-12-04 | Kenkare-mitra Sara (President and Head of R&D) | Sale | 12,519 | 5.56 | 69,605 |
| 2023-12-04 | Romano Gary (Chief Medical Officer) | Sale | 5,035 | 5.56 | 27,994 |
| 2023-12-04 | Rosenthal Arnon (Chief Executive Officer) | Sale | 23,831 | 5.56 | 132,500 |
| 2023-12-04 | Grasso Marc (Chief Financial Officer) | Sale | 4,574 | 5.56 | 25,431 |
| 2023-09-11 | Polaris Venture Partners Vi (aiv-b), L.p. (10% Owner) | Sale | 500,000 | 6.00 | 3,000,000 |
| 2023-09-11 | Mcguire Terrance (Director) | Sale | 500,000 | 6.00 | 3,000,000 |
| 2023-09-05 | Kenkare-mitra Sara (President and Head of R&D) | Sale | 6,214 | 5.19 | 32,275 |
| 2023-09-05 | Romano Gary (Chief Medical Officer) | Sale | 2,771 | 5.19 | 14,392 |
| 2023-09-05 | Rosenthal Arnon (Chief Executive Officer) | Sale | 5,647 | 5.20 | 29,336 |
| 2023-09-05 | Grasso Marc (Chief Financial Officer) | Sale | 1,114 | 5.19 | 5,786 |
| 2023-06-02 | Kenkare-mitra Sara (President and Head of R&D) | Sale | 4,092 | 6.90 | 28,251 |
| 2023-06-02 | Romano Gary (Chief Medical Officer) | Sale | 2,617 | 6.90 | 18,067 |
| 2023-06-02 | Rosenthal Arnon (Chief Executive Officer) | Sale | 5,255 | 6.90 | 36,280 |
| 2023-06-02 | Grasso Marc (Chief Financial Officer) | Sale | 1,050 | 6.90 | 7,249 |
| 2023-03-17 | Rosenthal Arnon (Chief Executive Officer) | Sale | 15,186 | 6.22 | 94,426 |
| 2023-03-02 | Kenkare-mitra Sara (President and Head of R&D) | Sale | 10,124 | 8.32 | 84,221 |
| 2023-03-02 | Romano Gary (Chief Medical Officer) | Sale | 3,238 | 8.32 | 26,933 |
| 2023-03-02 | Rosenthal Arnon (Chief Executive Officer) | Sale | 5,849 | 8.32 | 48,651 |
| 2023-03-02 | Grasso Marc (Chief Financial Officer) | Sale | 1,291 | 8.32 | 10,738 |
| 2022-12-02 | Romano Gary (Chief Medical Officer) | Sale | 2,145 | 8.71 | 18,678 |
| 2022-06-02 | King Robert (Chief Development Officer) | Sale | 177 | 8.71 | 1,541 |
| 2022-03-01 | King Robert (Chief Development Officer) | Sale | 287 | 15.57 | 4,468 |
| 2021-12-13 | Suliman Shehnaaz (President and COO) | Sale | 75,000 | 21.44 | 1,608,300 |
| 2021-12-13 | Suliman Shehnaaz (President and COO) | Option Ex | 75,000 | 17.23 | 1,292,250 |
| 2021-12-10 | Suliman Shehnaaz (President and COO) | Sale | 75,000 | 22.01 | 1,650,750 |
| 2021-12-10 | Suliman Shehnaaz (President and COO) | Option Ex | 75,000 | 17.23 | 1,292,250 |
| 2021-12-09 | Suliman Shehnaaz (President and COO) | Sale | 75,000 | 23.10 | 1,732,800 |
| 2021-12-09 | Suliman Shehnaaz (President and COO) | Option Ex | 75,000 | 17.23 | 1,292,250 |
| 2021-12-08 | Suliman Shehnaaz (President and COO) | Sale | 75,000 | 22.79 | 1,708,875 |
| 2021-12-08 | Suliman Shehnaaz (President and COO) | Option Ex | 75,000 | 13.73 | 1,030,125 |
| 2021-12-01 | King Robert (Chief Development Officer) | Sale | 250 | 20.09 | 5,022 |
| 2021-11-11 | Rosenthal Arnon (Chief Executive Officer) | Sale | 55,000 | 25.00 | 1,375,000 |
| 2021-11-10 | Rosenthal Arnon (Chief Executive Officer) | Sale | 55,000 | 25.00 | 1,375,000 |
| 2021-11-09 | Rosenthal Arnon (Chief Executive Officer) | Sale | 100,000 | 25.00 | 2,500,000 |
| 2021-11-08 | Rosenthal Arnon (Chief Executive Officer) | Sale | 100,000 | 25.00 | 2,500,000 |
| 2021-11-05 | Rosenthal Arnon (Chief Executive Officer) | Sale | 100,000 | 25.00 | 2,500,000 |
| 2021-11-04 | Rosenthal Arnon (Chief Executive Officer) | Sale | 100,000 | 25.00 | 2,500,000 |
| 2021-09-23 | Rosenthal Arnon (Chief Executive Officer) | Sale | 9,625 | 25.10 | 241,568 |
| 2021-09-22 | Rosenthal Arnon (Chief Executive Officer) | Sale | 100,000 | 25.70 | 2,569,500 |
| 2021-09-21 | Rosenthal Arnon (Chief Executive Officer) | Sale | 100,000 | 26.32 | 2,631,600 |
| 2021-09-20 | Rosenthal Arnon (Chief Executive Officer) | Sale | 100,000 | 26.04 | 2,604,400 |
| 2021-09-10 | Yaffe Kristine (Director) | Option Ex | 2,000 | 18.10 | 36,200 |
| 2021-08-09 | Paul Robert (Chief Medical Officer) | Sale | 22,950 | 27.48 | 630,688 |
| 2021-08-09 | Paul Robert (Chief Medical Officer) | Option Ex | 22,950 | 11.82 | 271,200 |
| 2021-08-05 | Scheller Richard H (Director) | Sale | 56,260 | 27.97 | 1,573,704 |
| 2021-08-05 | Scheller Richard H (Director) | Option Ex | 56,260 | 10.14 | 570,476 |
| 2021-07-07 | Paul Robert (Chief Medical Officer) | Sale | 29,749 | 38.29 | 1,139,089 |
| 2021-07-07 | Paul Robert (Chief Medical Officer) | Option Ex | 29,749 | 11.82 | 351,543 |
| 2021-07-06 | Paul Robert (Chief Medical Officer) | Sale | 30,000 | 37.71 | 1,131,270 |
| 2021-07-06 | Paul Robert (Chief Medical Officer) | Option Ex | 30,000 | 17.15 | 514,499 |
| 2021-07-06 | Yu Calvin (Vice President, Finance) | Sale | 3,334 | 34.65 | 115,523 |
| 2021-07-06 | Yu Calvin (Vice President, Finance) | Option Ex | 3,334 | 11.82 | 39,397 |
| 2021-07-02 | Paul Robert (Chief Medical Officer) | Sale | 30,000 | 31.14 | 934,200 |
| 2021-07-02 | Paul Robert (Chief Medical Officer) | Option Ex | 17,326 | 17.15 | 297,140 |
| 2021-07-02 | Yu Calvin (Vice President, Finance) | Sale | 110,840 | 35.58 | 3,943,465 |
| 2021-07-02 | Yu Calvin (Vice President, Finance) | Option Ex | 60,840 | 11.82 | 718,946 |
| 2021-07-02 | King Robert (Chief Development Officer) | Sale | 60,000 | 31.14 | 1,868,400 |
| 2021-07-02 | King Robert (Chief Development Officer) | Option Ex | 60,000 | 9.15 | 549,000 |
| 2021-07-02 | Scheller Richard H (Director) | Sale | 9,981 | 31.14 | 310,808 |
| 2021-07-01 | Paul Robert (Chief Medical Officer) | Sale | 26,726 | 22.23 | 594,118 |
| 2021-05-21 | Paul Robert (Chief Medical Officer) | Sale | 14,975 | 18.14 | 271,676 |
| 2021-05-21 | Paul Robert (Chief Medical Officer) | Option Ex | 14,975 | 9.15 | 137,021 |
| 2021-05-18 | Paul Robert (Chief Medical Officer) | Sale | 4,200 | 18.04 | 75,784 |
| 2021-05-18 | Paul Robert (Chief Medical Officer) | Option Ex | 4,200 | 9.15 | 38,430 |
| 2021-04-07 | Paul Robert (Chief Medical Officer) | Sale | 22,300 | 19.51 | 435,117 |
| 2021-04-07 | Paul Robert (Chief Medical Officer) | Option Ex | 22,300 | 11.82 | 263,519 |
| 2021-03-23 | Paul Robert (Chief Medical Officer) | Sale | 13,800 | 22.21 | 306,498 |
| 2021-03-23 | Paul Robert (Chief Medical Officer) | Option Ex | 13,800 | 8.16 | 112,608 |
| 2021-03-22 | Paul Robert (Chief Medical Officer) | Sale | 30,000 | 23.20 | 696,030 |
| 2021-03-22 | Paul Robert (Chief Medical Officer) | Option Ex | 30,000 | 8.16 | 244,800 |
| 2021-03-09 | Paul Robert (Chief Medical Officer) | Sale | 19,175 | 18.12 | 347,412 |
| 2021-03-09 | Paul Robert (Chief Medical Officer) | Option Ex | 19,175 | 9.15 | 175,451 |
| 2021-02-09 | Paul Robert (Chief Medical Officer) | Sale | 19,175 | 20.81 | 399,050 |
| 2021-02-09 | Paul Robert (Chief Medical Officer) | Option Ex | 19,175 | 9.15 | 175,451 |
| 2021-01-26 | Paul Robert (Chief Medical Officer) | Sale | 27,308 | 18.00 | 491,544 |
| 2021-01-26 | Paul Robert (Chief Medical Officer) | Option Ex | 27,308 | 9.15 | 249,868 |
| 2021-01-25 | Paul Robert (Chief Medical Officer) | Sale | 30,000 | 18.01 | 540,240 |
| 2021-01-25 | Paul Robert (Chief Medical Officer) | Option Ex | 30,000 | 9.15 | 274,500 |
| 2021-01-20 | Paul Robert (Chief Medical Officer) | Sale | 8,567 | 18.00 | 154,214 |
| 2021-01-20 | Paul Robert (Chief Medical Officer) | Option Ex | 8,567 | 9.15 | 78,388 |
| 2021-01-19 | Paul Robert (Chief Medical Officer) | Sale | 30,000 | 18.12 | 543,540 |
| 2021-01-19 | Paul Robert (Chief Medical Officer) | Option Ex | 30,000 | 9.15 | 274,500 |
| 2020-07-15 | Paul Robert (Chief Medical Officer) | Sale | 10,000 | 23.26 | 232,600 |
| 2020-06-23 | Pvp Vi (aiv) Feeder Corp. Holding Partnership, L.p. (10% Owner) | Sale | 4,377 | 31.54 | 138,063 |
| 2020-06-23 | Mcguire Terrance (Director) | Sale | 4,377 | 31.54 | 138,063 |
| 2020-06-15 | Paul Robert (Chief Medical Officer) | Sale | 10,000 | 29.66 | 296,650 |
| 2020-06-03 | Yu Calvin (Vice President, Finance) | Sale | 1,343 | 31.53 | 42,344 |
| 2020-05-15 | Paul Robert (Chief Medical Officer) | Sale | 10,000 | 26.98 | 269,770 |
| 2020-05-15 | King Robert (Chief Development Officer) | Sale | 15,000 | 27.01 | 405,195 |
| 2020-04-16 | Orbimed Capital Gp Iv Llc | Sale | 62,183 | 23.53 | 1,463,165 |
| 2020-04-15 | Paul Robert (Chief Medical Officer) | Sale | 10,000 | 22.27 | 222,700 |
| 2020-04-14 | Orbimed Capital Gp Iv Llc | Sale | 23,231 | 23.52 | 546,393 |
| 2020-04-09 | Orbimed Capital Gp Iv Llc | Sale | 288,101 | 23.79 | 6,853,922 |
| 2020-04-08 | Orbimed Capital Gp Iv Llc | Sale | 82,614 | 23.65 | 1,953,821 |
| 2020-04-07 | Orbimed Capital Gp Iv Llc | Sale | 9,170 | 23.10 | 211,827 |
| 2020-03-31 | Orbimed Capital Gp Iv Llc | Sale | 250,000 | 24.50 | 6,125,000 |
| 2020-03-25 | Orbimed Capital Gp Iv Llc | Sale | 56,411 | 24.66 | 1,391,095 |
| 2020-03-24 | Orbimed Capital Gp Iv Llc | Sale | 67,644 | 24.45 | 1,653,895 |
| 2020-03-23 | Orbimed Capital Gp Iv Llc | Sale | 14,598 | 26.05 | 380,277 |
| 2020-03-13 | Paul Robert (Chief Medical Officer) | Sale | 10,000 | 23.00 | 229,980 |
| 2020-03-02 | Orbimed Capital Llc | Sale | 1,874,203 | 26.00 | 48,729,278 |
| 2020-02-14 | Paul Robert (Chief Medical Officer) | Sale | 10,000 | 29.41 | 294,050 |
| 2020-02-14 | King Robert (Chief Development Officer) | Sale | 15,000 | 29.43 | 441,450 |
| 2020-02-07 | Yu Calvin (Vice President, Finance) | Sale | 24,033 | 35.02 | 841,635 |
| 2020-02-07 | Yu Calvin (Vice President, Finance) | Option Ex | 10,225 | 9.15 | 93,558 |
| 2020-02-07 | Oney Sabah (Chief Business Officer) | Sale | 19,900 | 35.03 | 697,097 |
| 2020-02-06 | Yu Calvin (Vice President, Finance) | Sale | 2,621 | 35.00 | 91,735 |
| 2020-02-06 | Yu Calvin (Vice President, Finance) | Option Ex | 1,821 | 9.15 | 16,662 |
| 2020-02-06 | Oney Sabah (Chief Business Officer) | Sale | 100 | 35.00 | 3,500 |
| 2020-02-05 | Paul Robert (Chief Medical Officer) | Sale | 10,000 | 32.10 | 321,000 |
| 2020-02-05 | Paul Robert (Chief Medical Officer) | Option Ex | 10,000 | 8.16 | 81,600 |
| 2020-02-04 | Yu Calvin (Vice President, Finance) | Sale | 63,541 | 30.04 | 1,908,771 |
| 2020-02-04 | Yu Calvin (Vice President, Finance) | Option Ex | 13,541 | 8.16 | 110,494 |
| 2020-02-04 | Oney Sabah (Chief Business Officer) | Sale | 16,667 | 30.00 | 500,010 |
| 2020-02-04 | Oney Sabah (Chief Business Officer) | Option Ex | 16,667 | 8.16 | 136,002 |
| 2020-02-04 | Scheller Richard H (Director) | Sale | 10,000 | 29.67 | 296,700 |
| 2020-02-03 | Wehner David M. (Director) | Buy | 20,000 | 25.00 | 500,000 |
| 2020-01-30 | Paul Robert (Chief Medical Officer) | Sale | 8,000 | 28.00 | 224,000 |
| 2020-01-30 | Paul Robert (Chief Medical Officer) | Option Ex | 8,000 | 8.16 | 65,280 |
| 2020-01-27 | Oney Sabah (Chief Business Officer) | Sale | 14,467 | 25.05 | 362,398 |
| 2020-01-27 | Oney Sabah (Chief Business Officer) | Option Ex | 14,467 | 8.16 | 118,050 |
| 2020-01-23 | Paul Robert (Chief Medical Officer) | Sale | 6,000 | 24.72 | 148,320 |
| 2020-01-23 | Paul Robert (Chief Medical Officer) | Option Ex | 6,000 | 8.16 | 48,960 |
| 2020-01-23 | Oney Sabah (Chief Business Officer) | Sale | 2,200 | 25.21 | 55,462 |
| 2020-01-23 | Oney Sabah (Chief Business Officer) | Option Ex | 2,200 | 8.16 | 17,952 |
| 2020-01-22 | King Robert (Chief Development Officer) | Sale | 3 | 22.01 | 66 |
| 2020-01-21 | King Robert (Chief Development Officer) | Sale | 14,997 | 22.01 | 330,083 |
| 2020-01-15 | Paul Robert (Chief Medical Officer) | Sale | 10,000 | 18.67 | 186,700 |
| 2020-01-09 | Orbimed Capital Llc | Sale | 379,997 | 19.50 | 7,409,941 |
| 2019-12-26 | Orbimed Capital Llc | Sale | 10,800 | 18.60 | 200,880 |
| 2019-12-24 | Orbimed Capital Llc | Sale | 71,800 | 19.59 | 1,406,562 |
| 2019-12-23 | Orbimed Capital Llc | Sale | 94,285 | 19.82 | 1,868,728 |
| 2019-12-20 | Orbimed Capital Llc | Sale | 342,500 | 19.66 | 6,733,550 |
| 2019-12-17 | Orbimed Capital Llc | Sale | 954,100 | 18.52 | 17,669,932 |
| 2019-12-13 | Paul Robert (Chief Medical Officer) | Sale | 10,000 | 20.03 | 200,300 |
| 2019-12-12 | Oney Sabah (Chief Business Officer) | Sale | 6,810 | 20.13 | 137,071 |
| 2019-12-12 | Oney Sabah (Chief Business Officer) | Option Ex | 6,810 | 8.16 | 55,569 |
| 2019-12-10 | Oney Sabah (Chief Business Officer) | Sale | 500 | 20.01 | 10,005 |
| 2019-12-10 | Oney Sabah (Chief Business Officer) | Option Ex | 500 | 8.16 | 4,080 |
| 2019-12-09 | Oney Sabah (Chief Business Officer) | Sale | 2,300 | 20.07 | 46,161 |
| 2019-12-09 | Oney Sabah (Chief Business Officer) | Option Ex | 2,300 | 8.16 | 18,768 |
| 2019-12-06 | Oney Sabah (Chief Business Officer) | Sale | 5,156 | 20.02 | 103,223 |
| 2019-12-06 | Oney Sabah (Chief Business Officer) | Option Ex | 5,156 | 8.16 | 42,072 |
| 2019-12-05 | Oney Sabah (Chief Business Officer) | Sale | 1,500 | 20.00 | 30,000 |
| 2019-12-05 | Oney Sabah (Chief Business Officer) | Option Ex | 1,500 | 8.16 | 12,240 |
| 2019-12-03 | Yu Calvin (Vice President, Finance) | Sale | 1,315 | 18.31 | 24,077 |
| 2019-11-15 | Paul Robert (Chief Medical Officer) | Sale | 10,000 | 15.93 | 159,300 |
| 2019-11-15 | King Robert (Chief Development Officer) | Sale | 7,500 | 15.92 | 119,400 |
| 2019-10-15 | Paul Robert (Chief Medical Officer) | Sale | 10,000 | 14.68 | 146,800 |
| 2019-09-20 | Paul Robert (Chief Medical Officer) | Sale | 4,000 | 20.00 | 80,000 |
| 2019-09-20 | Paul Robert (Chief Medical Officer) | Option Ex | 4,000 | 8.16 | 32,640 |
| 2019-09-20 | Oney Sabah (Chief Business Officer) | Sale | 400 | 20.00 | 8,000 |
| 2019-09-20 | Oney Sabah (Chief Business Officer) | Option Ex | 400 | 8.16 | 3,264 |
| 2019-09-16 | Paul Robert (Chief Medical Officer) | Sale | 10,000 | 19.08 | 190,799 |
| 2019-08-20 | Paul Robert (Chief Medical Officer) | Sale | 916 | 16.00 | 14,656 |
| 2019-08-19 | Paul Robert (Chief Medical Officer) | Sale | 1,084 | 16.00 | 17,344 |
| 2019-08-19 | King Robert (Chief Development Officer) | Sale | 7,500 | 15.00 | 112,500 |
| 2019-08-15 | Paul Robert (Chief Medical Officer) | Sale | 10,000 | 14.19 | 141,900 |
| 2019-08-07 | Orbimed Capital Llc | Sale | 650,000 | 17.90 | 11,635,000 |
| 2019-02-11 | Gordon Carl L (Director) | Buy | 411,700 | 19.00 | 7,822,300 |
| 2019-02-11 | Orbimed Capital Llc (Director) | Buy | 411,700 | 19.00 | 7,822,300 |
Insider trading activities including stock purchases, stock sales, and option exercises of ALEC listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Alector, Inc. (symbol ALEC, CIK number 1653087) see the Securities and Exchange Commission (SEC) website.